首页> 美国卫生研究院文献>Springer Open Choice >Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

【2h】

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

机译：一线治疗转移性去势抵抗性前列腺癌的现实结果：前列腺癌注册中心

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version of this article (10.1007/s11523-020-00720-2) contains supplementary material, which is available to authorized users.

机译：本文的在线版本（10.1007 / s11523-020-00720-2）包含补充材料，可供授权用户使用。

著录项

期刊名称 Springer Open Choice
作者
Simon Chowdhury; Anders Bjartell; Nicolaas Lumen; Pablo Maroto; Thomas Paiss; Francisco Gomez-Veiga; Alison Birtle; Gero Kramer; Ewa Kalinka; Dominique Spaëth; Susan Feyerabend; Vsevolod Matveev; Florence Lefresne; Martin Lukac; Robert Wapenaar; Luis Costa;
展开▼
作者单位

展开▼
年(卷),期 -1(15),3
年度 -1
页码 -1
总页数 15
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry [J] . Targeted oncology . 2020,第3期

机译：第一线治疗转移性阉割前列腺癌的现实世界结果：前列腺癌登记处
2. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting [J] . William K. Oh, Wendy Y. Cheng, Raymond Miao, Urologic oncology . 2018,第11期

机译：在美国社区肿瘤学环境中，在早期进展之前，在美国社区肿瘤环境中的一线arta患者接受二线化疗患者的现实世界结果与替代雄激素受体靶向剂（ARTA）
3. Re: First-Line Treatment in Senior Adults with Metastatic Castration-Resistant Prostate Cancer: A Prospective International Registry [J] . Griebling Tomas L. The Journal of Urology . 2017,第1期

机译：RE：高级成人的一线治疗，具有转移性阉割前列腺癌：一个潜在的国际登记处
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Clinical outcomes of First-line Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [O] . Edoardo Francini, Steven Yip, Shubidito Ahmed, -1

机译：一线醋酸阿比特龙（AA）或恩扎鲁胺（E）用于雄激素剥夺疗法（ADT）+多西他赛（D）或仅ADT用于转移性激素敏感性前列腺癌（mHSPC）的转移性去势抵抗性前列腺癌（mCRPC）的临床结果
7. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry [O] . Anders Bjartell, Nicolaas Lumen, Pablo Maroto, 2021

机译：与AbiraTerone醋酸盐加上泼尼松或泼尼松龙作为转移性阉割前列腺癌的第一或第二线治疗的现实世界的安全和疗效结果：来自前列腺癌登记处的数据

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

摘要

著录项

相似文献

相关主题

期刊订阅